Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center

(2015) Klaudia Farkas et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Infection risk associated with anti-TNF-α agents: a review

(2015) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

(2015) Filip Baert et al.   GUT

Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohnʼs Disease

(2015) David L. Suskind et al.   INFLAMMATORY BOWEL DISEASES

Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohnʼs Disease

(2015) Yasuo Suzuki et al.   INFLAMMATORY BOWEL DISEASES

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis

(2015) Rajendrakumar H. Jani et al.   International Journal of Rheumatic Diseases

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

(2015) Niels Vande Casteele et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

(2015) Yoon Suk Jung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease

(2015) Yao Wei et al.   Gastroenterology Research and Practice

Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience

(2015) Ofer Ben-Bassat et al.   GASTROENTEROLOGY

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

(2014) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry

(2014) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Review of CT-P13: An Infliximab Biosimilar

(2014) Kate McKeage   BIODRUGS

The use of biologic therapy in pregnancy

(2014) Benjamin Hassid et al.   CURRENT OPINION IN RHEUMATOLOGY

Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

(2014) Joseph D. Feuerstein et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease

(2014) C. Gagniere et al.   Journal of Crohns & Colitis

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

(2014) J.F. Rahier et al.   Journal of Crohns & Colitis

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

(2014) David J. Shealy et al.   mAbs

Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies

(2014) Lior H. Katz et al.   Clinics and Research in Hepatology and Gastroenterology

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

(2013) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Safety of TNF-α inhibitors during IBD pregnancy: a systematic review

(2013) Ole Haagen Nielsen et al.   BMC Medicine

Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project

(2013) B. Nardone et al.   BRITISH JOURNAL OF DERMATOLOGY

Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?

(2013) Angelos Oikonomopoulos et al.   CURRENT DRUG TARGETS

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

(2013) Mark T. Osterman et al.   GASTROENTEROLOGY

AVX-470

(2013) Kailash C. Bhol et al.   INFLAMMATORY BOWEL DISEASES

Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease

(2013) Sorcha O’Meara et al.   INFLAMMATORY BOWEL DISEASES

Opportunistic Infections Due to Inflammatory Bowel Disease Therapy

(2013) Maneesh Dave et al.   INFLAMMATORY BOWEL DISEASES

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease

(2013) Toshifumi Hibi et al.   JOURNAL OF GASTROENTEROLOGY

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

(2013) P. Raaschou et al.   BMJ-British Medical Journal

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

(2012) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis

(2012) William J Sandborn et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Signal transduction by tumor necrosis factor receptors

(2012) Lucía Cabal-Hierro et al.   CELLULAR SIGNALLING

Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease

(2012) Millie D. Long et al.   GASTROENTEROLOGY

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

(2012) Mirthe Emilie van der Valk et al.   GUT

Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease

(2012) Derek H. Tang et al.   PHARMACOTHERAPY

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

(2011) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease

(2011) Daniel W. Hommes et al.   Journal of Crohns & Colitis

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine

(2010) T. Tang et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease

(2010) H.-C. REINECKER et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease

(2010) W. Miehsler et al.   Journal of Crohns & Colitis

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

(2010) Charlotte Krieckaert et al.   ARTHRITIS RESEARCH & THERAPY

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies

(2009) M. ALLEZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serum sickness, encephalitis and other complications of anti-cytokine therapy

(2009) Séverine Vermeire et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Certolizumab pegol for the management of Crohn's disease in adults

(2009) Anastasia Rivkin   CLINICAL THERAPEUTICS

Differences in binding and effector functions between classes of TNF antagonists

(2009) Taruna Arora et al.   CYTOKINE

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Safety Profile of IBD Therapeutics: Infectious Risks

(2009) Waqqas Afif et al.   MEDICAL CLINICS OF NORTH AMERICA

Controlling the cost of innovative cancer therapeutics

(2009) Nafees N. Malik   Nature Reviews Clinical Oncology

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

(2008) Hiroki Mitoma et al.   ARTHRITIS AND RHEUMATISM

The Impact of PEGylation on Biological Therapies

(2008) Francesco M Veronese et al.   BIODRUGS

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

(2008) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology

Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

(2008) Murat Toruner et al.   GASTROENTEROLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS